"Challenge" Pfizer! Zhengda Qingjiang's 4 generic drugs are about to be approved

ZhengdaQingjiang Ceresibu review timelineSerexibu capsule is the world's first selective nonsteroidal anti-inflammatory analgesics, used to relieve the symptoms and signs of osteoarthritis, relieve the symptoms and signs of rheumatoid arthritis in humans, treat acute pain in adults, relieve the symptoms and signs of severe syllitisThe Ceresibu capsule, originally developed as Pfizer's Ceres, was first approved by the FDA in 1998 and approved by the State Drug Administration in October 2012according to, sales of terminals in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public health institutions) in 2018 were 1.025 billion yuan, up 25.28 percent year-on-yearOn November 29, 2019, Hengrui Pharmaceutical Selaixibu capsules were approved for the market by the State Drug Administration, and the first imitation of the species was takenZheng Daqingjiang followed suit and will soon be approved for listingChina's public medical institutions terminal Ceresibu capsule sales (unit: million yuan)at present, there are a number of enterprises in the layout of Ceresibu generic drugsMinet data show that according to the four types of generic drugs submitted to the listing application of the domestic enterprises a total of 10Hengrui Pharmaceuticals, Zhengda Qingjiang, Baiyang Pharmaceuticals, Shi medicine Ouyi has been included in the CDE priority reviewAt present, the stone medicine O'Yi, Qilu pharmaceutical, Yabao Pharmaceutical and other 8 enterprises the product is still in the state of review and approvalThe listing of a class 4 generic drug in Theresibdata source: Ricenet databaseoriginal title: "Review" "Challenge" Pfizer! 1 billion anti-inflammatory analgesics zheng Daqingjiang will enter the game